Glycosylation, a prevalent post-translational modification, plays a pivotal role in regulating intricate cellular processes by covalently attaching glycans to macromolecules. Dysregulated glycosylation is linked to a spectrum of diseases, encompassing cancer, neurodegenerative disorders, congenital disorders, infections, and inflammation. This review delves into the intricate interplay between glycosylation and protein conformation, with a specific focus on the profound impact of N-glycans on the selection of distinct protein conformations characterized by distinct interactomes—namely, protein assemblies—under normal and pathological conditions across various diseases. We begin by examining the spike protein of the SARS virus, illustrating how N-glycans regulate the infectivity of pathogenic agents. Subsequently, we utilize the prion protein and the chaperone glucose-regulated protein 94 as examples, exploring instances where N-glycosylation transforms physiological protein structures into disease-associated forms. Unraveling these connections provides valuable insights into potential therapeutic avenues and a deeper comprehension of the molecular intricacies that underlie disease conditions. This exploration of glycosylation’s influence on protein conformation effectively bridges the gap between the glycome and disease, offering a comprehensive perspective on the therapeutic implications of targeting conformational mutants and their pathologic assemblies in various diseases. The goal is to unravel the nuances of these post-translational modifications, shedding light on how they contribute to the intricate interplay between protein conformation, assembly, and disease.
Neurodegenerative disorders, including Alzheimer’s disease (AD) and Parkinson’s disease (PD), represent debilitating conditions with complex, poorly understood pathologies. Epichaperomes, pathologic protein assemblies nucleated on key chaperones, have emerged as critical players in the molecular dysfunction underlying these disorders. In this study, we introduce the synthesis and characterization of clickable epichaperome probes, PU-TCO, positive control, and PU-NTCO, negative control. Through comprehensive in vitro assays and cell-based investigations, we establish the specificity of the PU-TCO probe for epichaperomes. Furthermore, we demonstrate the efficacy of PU-TCO in detecting epichaperomes in brain tissue with a cellular resolution, underscoring its potential as a valuable tool for dissecting single-cell responses in neurodegenerative diseases. This clickable probe is therefore poised to address a critical need in the field, offering unprecedented precision and versatility in studying epichaperomes and opening avenues for novel insights into their role in disease pathology.
Glycosylation, a prevalent post-translational modification, plays a pivotal role in regulating intricate cellular processes by covalently attaching glycans to macromolecules. Dysregulated glycosylation is linked to a spectrum of diseases, encompassing cancer, neurodegenerative disorders, congenital disorders, infections, and inflammation. This review delves into the intricate interplay between glycosylation and protein conformation, with a specific focus on the profound impact of N-glycans on the selection of distinct protein conformations, characterized by distinct interactomes – namely protein assemblies - under normal and pathological conditions across various diseases. We begin by examining the spike protein of the SARS virus, illustrating how N-glycans regulate the infectivity of pathogenic agents. Subsequently, we utilize the prion protein and the chaperone glucose-regulated protein 94 as examples, exploring instances where N-glycosylation transforms physiological protein structures into disease-associated forms. Unraveling these connections provides valuable insights into potential therapeutic avenues and a deeper comprehension of the molecular intricacies that underlie disease conditions. This exploration of glycosylation's influence on protein conformation effectively bridges the gap between the glycome and disease, offering a comprehensive perspective on the therapeutic implications of targeting conformational mutants and their pathologic assemblies in various diseases. The goal is to unravel the nuances of these post-translational modifications, shedding light on how they contribute to the intricate interplay between protein conformation, assembly and disease.
24 October 2025 in Journal of Visualized Experiments
Protein-protein interaction (PPI) networks are dynamically remodeled in disease, yet most systems biology approaches focus on changes in protein abundance, overlooking critical interaction-level dysfunction. Here, we present a robust, chemoproteomic method-dysfunctional Protein-Protein Interactome (dfPPI)-that enables high-throughput, systematic, disease-contextual mapping of PPI network dysfunctions in cells and primary human tissue. This method integrates chemical biology probes that selectively capture epichaperome-based interactome assemblies with label-free liquid chromatography-tandem mass spectrometry (LC-MS/MS) and network-based computational analysis, to uncover the rewiring of protein networks not apparent from transcriptomic or proteomic data alone. The dfPPI platform can be applied across disease states, species, and tissues to identify actionable nodes of dysfunction and enable high-resolution, systems-level insights into disease progression. In this protocol, we demonstrate step-by-step procedures for sample preparation, chemical probe treatment, affinity enrichment, label-free LC-MS/MS analysis, and bioinformatics workflows used to generate and interpret dfPPI datasets. This article aims to promote reproducibility and accessibility of this approach, supporting its adoption by the broader systems biology and translational research communities.
Protein-protein interaction (PPI) networks are dynamically remodeled in disease, yet most systems biology approaches focus on changes in protein abundance, overlooking critical interaction-level dysfunction. Here, we present a robust, chemoproteomic method-dysfunctional Protein-Protein Interactome (dfPPI)-that enables high-throughput, systematic, disease-contextual mapping of PPI network dysfunctions in cells and primary human tissue. This method integrates chemical biology probes that selectively capture epichaperome-based interactome assemblies with label-free liquid chromatography-tandem mass spectrometry (LC-MS/MS) and network-based computational analysis, to uncover the rewiring of protein networks not apparent from transcriptomic or proteomic data alone. The dfPPI platform can be applied across disease states, species, and tissues to identify actionable nodes of dysfunction and enable high-resolution, systems-level insights into disease progression. In this protocol, we demonstrate step-by-step procedures for sample preparation, chemical probe treatment, affinity enrichment, label-free LC-MS/MS analysis, and bioinformatics workflows used to generate and interpret dfPPI datasets. This article aims to promote reproducibility and accessibility of this approach, supporting its adoption by the broader systems biology and translational research communities.